SCN2A and Lennox-Gastaut syndrome: Compounds that inhibit sodium channel function have therapeutic potential for gain-of-function (GOF) mutations, such as those identified in SCN2A (NaV1.2) and SCN8A (NaV1.6) in patients with LGS (Epi4K, 2013).